Alliance A071701: Genomically guided treatment trial in brain metastases., page-17

Yes needle, this research is also relevant to Paxalisib.

"Genes associated with increased brain metastasis risk in non–small cell lung cancer".
"Conclusions These findings yield detailed insights into the genomic complexity and heterogeneity of primary NSCLC and matched BMs. This study highlights the significant correlation of PI3K signaling with increased metastatic risk in patients with NSCLC and identifies genomic alterations enriched in NSCLC BMs that could serve as prognostic markers and potential therapeutic targets for treating patients with NSCLC BMs".

This study could lead to our next blue sky collaboration study in NSCLC BMs


"Genetic Evolution of Brain Metastases: Implications for Precision Medicine Priscilla Brastianos"

Priscilla Brastianos is a remarkable leading scientific researcher in BMs and I look forward to her presentation on 14 August.


"PI3K Inhibitors and Oral Taxanes for Metastatic Breast Cancer: Where Do They Fit In?"

"To be able to have a taxane that’s active, that has less neuropathy, that perhaps could even partner nicely with some other oral targeted therapies and have a doublet oral regimen, and that enables women to stay out of the infusion suite could be really advantageous,”

Alpelisib, Paclitaxel and several oral taxanes have efficacy and toxicity issues, also problems administering enough of the drug into the brain and past the blood brain barrier.
IMO Paxalisib should tick the necessary boxes in the Alliance study, especially in a COVID 19 environment where the patient can take one tablet from home.

Regards.